Home > Sci/Tech > Lamictal XR Approved

Lamictal XR Approved

Those with stakes in GlaxoSmithKline (NYSE: GSK) were pleased this morning as the stock rose on account of the FDA’s approval of Lamictal XR (“extended release”) . The drug, aimed at epilepsy patients thirteen years of age and older, is intended to reduce seizures in patients who have had unsuccessful results with other therapies.


My posts are not to serve as a replacement for recommendations provided by licensed physicians nor do they represent the opinions of Baylor College of Medicine or its affiliated institutions. Please read this site's Disclaimer and Terms of Use for more information.


Backup Your Data!

Over the years, I’ve helped my colleagues with recommendations for gadgets (namely laptops and smartphones) …

 One comment

  1. Not to mention that GlaxoSmithKline markets Relenza (Zanamivir), effective against A H1N1 (previously known as swine flu) and which is almost as good as Roche’s Tamiflu. 馃槈


Your email address will not be published. Required fields are marked *